CRTH2, or Chemoattractant receptor-homologous molecule expressed on TH2 cells or T Helper cells, is a G-protein coupled receptor. It is also expressed in basophils, eosinophils, and innate lymphoid cells. Prostaglandin D2 acts as a ligand on this receptor and mediates the production of type-2 cytokines like IL-4, IL-5, and IL-13, chemotaxis, and apoptosis. The PGD2-CRTH2 pathway is considered important for the development of allergic inflammation. Hence, CRTH2 Antagonists are used for controlling asthma due to allergies. Many candidates are in the pipeline for various indications for which CRTH2 Antagonists could be a possible treatment approach, like Asthma, Hypersensitivity, Dermatitis, Rhinitis, and others. To prevent and treat these diseases, businesses are looking for fresh, unique chemicals. Over the upcoming years, the THF dehydrogenase Inhibitor market will have a large increase in revenue due to the discovery and introduction of fresh products by industry participants. According to the Asthma and Allergy Foundation of America, in 2021, about 25 million people were suffering from Asthma (about 1 in every 13 Americans). About 5 million American children have asthma, according to the same report. Therefore, there is a rising trend in the prevalence of diseases in the CRTH2 Antagonists market and is an opportunity for the same.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. 18 companies have various products in their pipelines, with 20 products in various stages of clinical trials. 3 products are in Phase 3, 7 products are in Phase 2, and 10 products are in Phase 1 of the clinical trials.
Key Market Developments:
- In October 2018, Novartis drug Fevipiprant (QAW039 an oral competitive antagonist of CRTH2 have demonstrated safety and potential efficacy in patients with asthma, specifically, improvement in FEV1 and eosinophilic airway inflammation in Early-phase trials.
Drugs in Pipeline
- fevipiprant (QAW039)
- AZD1981
- timapiprant (OC000459)
- BI 671800 ED
- BI-144807
- setipiprant (ACT-129968)
- GB001
- MK-1029
- BI-1021958
- ARRY-502
- AZD5985
- AZD8075
- Baynas (ramatroban)
- CSPCHA115
- ATX2417
- BBI-5000
- MK-1092
- RG 7185
- TQC3564
- litapiprant (HEC46877)
Clinical Activity and Developments of CRTH2 Antagonists
As of June 2023, 18 companies have approximately 20 products for 34 diseases. For these diseases, about three trials are being conducted by players globally. For instance,
- KARE Biosciences is conducting a Phase 3 clinical trial to evaluate the efficacy and safety of Ramatroban along with the standard of care in subjects hospitalized for COVID pneumonia and is expected to complete by May 2026.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is conducting a Phase 1 clinical study to evaluate the efficacy and safety of TQC3564 tablets in the treatment of Persistent Allergic Rhinitis and is expected to complete by December 2023.
- Zhejiang Echon Biopharm Limited is conducting a Phase 1 clinical trial to evaluate the safety, Tolerability and Pharmacokinetic profiles of GB001 recombinant peptide spray in healthy subjects which was expected to complete by April 2023.
|
Molecule Name |
Number of Studies |
|
Fevipiprant (QAW039) |
19 |
|
AZD1981 |
16 |
|
Timapiprant (OC000459) |
14 |
|
BI 671800 ED |
9 |
|
BI-144807 |
7 |
Target Indication Analysis of CRTH2 Antagonists
Fevipiprant drug being developed by Novartis, is an oral reversible inhibitor of the PGD2 receptor that is being developed and currently tried in the 3rd Phase 3 clinical trials for the treatment of Asthma. It is also in clinical trials for other indications like Hypersensitivity, Eczema, Dermatitis, and others. Other drugs like Timapiprant are being developed by Atopis Therapeutics for the same indication as above and are in the 3rd Phase of clinical trials. AstraZeneca’s AZD1981 is a potent, fully reversible, functionally non-competitive antagonist of human CRTh2, which is under 2nd phase clinical trial for the indication of an uncontrolled asthma patient who has become unresponsive to inhaled steroids. Another phase 2 study also investigates the safety and efficacy of this drug class for COPD.
CRTH2 Antagonists Regional Analysis
CRTH2 Antagonists Market
According to the National Eczema Association, in 2022, about 31.6 million people in the USA have some form of eczema, with prevalence at peak during early childhood. It is estimated that 13% of Native Americans and Asian or Pacific Islanders, while 11% of white people have eczema in the USA. Approximately 9.6 million children under the age of 18 in the USA have Atopic Dermatitis (AD), while an estimated 16.5 million adults suffer from AD, of which 80% have experienced it prior to the age of 6. According to the report, over 55% of adults with moderate to severe AD report inadequate disease control. In Europe in 2023, according to a research report, more than 8% of adults and 8.4% to 18.6% of adolescents aged up to 18 have AD.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
Currently, no CRTH2 Antagonists have been approved by the FDA.
Asthma, Hypersensitivity, dermatitis, and Rhinitis are some of the primary indications for which CRTH2 Antagonists are being developed.
Novartis AG (Switzerland), Chiesi farmaceutici S.p.A. (Italy), AbbVie (USA), Teijin Pharma Ltd. (Japan), and Gossamer Bio (USA) are some of the major market players for CRTH2 Antagonists.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to various diseases like asthma, Atopic Dermatitis, and Rhinitis and increasing incidence of the diseases are the key opportunities for CRTH2 Antagonists in the market.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Novartis AG (Switzerland)
- Chiesi farmaceutici S.p.A. (Italy)
- AbbVie (USA)
- Teijin Pharma Ltd. (Japan)
- Gossamer Bio (USA)
- Boehringer Ingelheim (Germany)
- Pfizer (USA)
- AstraZeneca (USA)
- Bayer (Germany)
- KARE Biosciences Inc. (USA)
- CSPC Pharma (China)
- Fresh Tracks Therapeutics, Inc. (USA)
- Merck (MSD) (USA)
- Roche (Switzerland)
- Sino Biopharmaceuticals Co., Ltd. (Hong Kong)
- HEC Pharma Co., Ltd. (China)